Basel Medical Group Ltd
BMGL
$0.61
$0.024.05%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.63% | 8.12% | 3.03% | 3.97% | 4.84% |
| Total Other Revenue | -- | -12.50% | -89.91% | -94.96% | -100.00% |
| Total Revenue | 14.98% | 8.08% | 2.60% | 3.51% | 4.35% |
| Cost of Revenue | 54.73% | 53.09% | 53.75% | 28.73% | 7.15% |
| Gross Profit | -41.22% | -43.45% | -44.63% | -24.37% | 0.64% |
| SG&A Expenses | 4,333.33% | -74.74% | -88.36% | -94.04% | -99.70% |
| Depreciation & Amortization | 127.35% | 74.99% | 23.47% | 9.34% | -3.73% |
| Other Operating Expenses | 128.25% | 207.54% | 527.91% | 317.42% | 169.95% |
| Total Operating Expenses | 74.83% | 64.74% | 55.72% | 27.52% | 2.86% |
| Operating Income | -199.34% | -144.81% | -108.13% | -62.74% | 10.11% |
| Income Before Tax | -568.42% | -285.46% | -95.84% | -54.63% | 13.01% |
| Income Tax Expenses | -228.42% | -153.64% | -128.88% | -96.10% | -5.86% |
| Earnings from Continuing Operations | -622.68% | -322.69% | -83.12% | -41.87% | 16.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -622.66% | -322.68% | -83.12% | -41.87% | 16.75% |
| EBIT | -199.34% | -144.81% | -108.13% | -62.74% | 10.11% |
| EBITDA | -193.08% | -141.69% | -106.97% | -61.93% | 9.97% |
| EPS Basic | -501.69% | -269.08% | -83.12% | -41.84% | 16.91% |
| Normalized Basic EPS | -125.99% | -108.10% | -95.87% | -54.63% | 13.04% |
| EPS Diluted | -501.69% | -269.08% | -83.12% | -41.84% | 16.91% |
| Normalized Diluted EPS | -125.99% | -108.10% | -95.87% | -54.63% | 13.04% |
| Average Basic Shares Outstanding | 15.60% | 7.80% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 15.60% | 7.80% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |